Brian Elliott

1.3k total citations · 1 hit paper
32 papers, 482 citations indexed

About

Brian Elliott is a scholar working on Oncology, Pathology and Forensic Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Brian Elliott has authored 32 papers receiving a total of 482 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 13 papers in Pathology and Forensic Medicine and 10 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Brian Elliott's work include CAR-T cell therapy research (18 papers), Lymphoma Diagnosis and Treatment (12 papers) and Monoclonal and Polyclonal Antibodies Research (9 papers). Brian Elliott is often cited by papers focused on CAR-T cell therapy research (18 papers), Lymphoma Diagnosis and Treatment (12 papers) and Monoclonal and Polyclonal Antibodies Research (9 papers). Brian Elliott collaborates with scholars based in United States, United Kingdom and Denmark. Brian Elliott's co-authors include Kim Linton, Dena DeMarco, Roberto S Oliveri, Michael Roost Clausen, Martin Hutchings, Martine E.D. Chamuleau, Pieternella J. Lugtenburg, Rogier Mous, Peter Johnson and Anna Sureda and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Brian Elliott

29 papers receiving 474 citations

Hit Papers

Dose escalation of subcutaneous epcoritamab in patients w... 2021 2026 2022 2024 2021 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
    2021 212 citations Martin Hutchings, Rogier Mous et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Brian Elliott United States 11 359 261 115 95 88 32 482
Vincent Camus France 12 207 0.6× 319 1.2× 28 0.2× 89 0.9× 32 0.4× 48 527
Uri Abadi Israel 9 141 0.4× 129 0.5× 49 0.4× 35 0.4× 49 0.6× 28 298
Jean Michel Picquenot France 8 264 0.7× 318 1.2× 20 0.2× 68 0.7× 111 1.3× 11 598
Jens Samol Singapore 9 334 0.9× 219 0.8× 20 0.2× 39 0.4× 164 1.9× 33 537
Sami Ibrahimi United States 9 277 0.8× 158 0.6× 14 0.1× 66 0.7× 61 0.7× 33 387
Qingsong Yin China 8 156 0.4× 97 0.4× 29 0.3× 108 1.1× 97 1.1× 66 320
Alison N. Gencarelli United States 6 235 0.7× 431 1.7× 29 0.3× 307 3.2× 124 1.4× 7 532
Mariana Bastos‐Oreiro Spain 11 180 0.5× 126 0.5× 17 0.1× 68 0.7× 73 0.8× 51 363
Muhamad Alhaj Moustafa United States 10 121 0.3× 106 0.4× 19 0.2× 79 0.8× 44 0.5× 89 315
Ant Uzay Türkiye 8 126 0.4× 95 0.4× 23 0.2× 92 1.0× 96 1.1× 21 433

Countries citing papers authored by Brian Elliott

Since Specialization
Citations

This map shows the geographic impact of Brian Elliott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Elliott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Elliott more than expected).

Fields of papers citing papers by Brian Elliott

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Elliott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Elliott. The network helps show where Brian Elliott may publish in the future.

Co-authorship network of co-authors of Brian Elliott

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Elliott. A scholar is included among the top collaborators of Brian Elliott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Elliott. Brian Elliott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ip, Andrew, et al.. (2024). Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data Analysis. Advances in Therapy. 41(3). 1226–1244. 5 indexed citations
2.
Rosenthal, Allison, Javier Muñoz, Tongsheng Wang, et al.. (2023). P1149: COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB-BASED REGIMENS, AND TAFASITAMAB-BASED REGIMENS. HemaSphere. 7(S3). e9299527–e9299527.
3.
Sehn, Laurie H., Martine E.D. Chamuleau, Georg Lenz, et al.. (2023). ABCL-517 Phase III Trial of Subcutaneous Epcoritamab + R-CHOP Versus R-CHOP Alone in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): EPCORE DLBCL-2. Clinical Lymphoma Myeloma & Leukemia. 23. S440–S440. 1 indexed citations
4.
Li, Tommy, Ida H. Hiemstra, Christopher Chiu, et al.. (2022). Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas. Clinical Pharmacology & Therapeutics. 112(5). 1108–1119. 25 indexed citations
5.
Falchi, Lorenzo, Sirpa Leppä, Björn E. Wahlin, et al.. (2022). Subcutaneous epcoritamab with rituximab + lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial.. Journal of Clinical Oncology. 40(16_suppl). 7524–7524. 12 indexed citations
6.
7.
Hutchings, Martin, Rogier Mous, Michael Roost Clausen, et al.. (2021). Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. The Lancet. 398(10306). 1157–1169. 212 indexed citations breakdown →
8.
Hutchings, Martin, Rogier Mous, Michael Roost Clausen, et al.. (2021). SUBCUTANEOUS EPCORITAMAB IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA: SAFETY PROFILE AND ANTI‐TUMOR ACTIVITY. Hematological Oncology. 39(S2). 1 indexed citations
9.
Clausen, Michael Roost, Pieternella J. Lugtenburg, Martin Hutchings, et al.. (2021). Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity.. Journal of Clinical Oncology. 39(15_suppl). 7518–7518. 14 indexed citations
10.
Hutchings, Martin, Pieternella J. Lugtenburg, Rogier Mous, et al.. (2020). Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial.. Journal of Clinical Oncology. 38(15_suppl). 8009–8009. 19 indexed citations
11.
Tremblay, Gabriel, et al.. (2018). Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia. ClinicoEconomics and Outcomes Research. Volume 10. 705–713. 8 indexed citations
12.
Tremblay, Gabriel, Menaka Bhor, Qayyim Said, et al.. (2018). Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia. ClinicoEconomics and Outcomes Research. Volume 10. 715–721. 7 indexed citations
13.
Tremblay, Gabriel, Menaka Bhor, Anuja Roy, et al.. (2017). Cost-Consequence Model Comparing Eltrombopag and Romiplostim for Pediatric Patients with Previously-Treated Chronic Immune Thrombocytopenia. Blood. 130. 2146–2146. 1 indexed citations
14.
Hao, Yanni, Alex Z. Fu, Ying Qiu, et al.. (2016). Clinical Outcomes Among Patients with Myelodysplastic Syndromes Treated with Iron Chelation Therapy: A Real World Medicare Database Study. Blood. 128(22). 2396–2396. 2 indexed citations
15.
Maziarz, Richard T., Bart L. Scott, Sanjay Mohan, et al.. (2015). A phase II, randomized trial of standard of care with or without midostaurin to prevent relapse following allogeneic stem cell transplantation in patients with FLT3-ITD mutated acute myeloid leukemia.. Journal of Clinical Oncology. 33(15_suppl). TPS7094–TPS7094. 2 indexed citations
16.
Elliott, Brian & Louis M. Aledort. (2013). Restoring hemostasis: fibrinogen concentrate versus cryoprecipitate. Expert Review of Hematology. 6(3). 277–286. 14 indexed citations
17.
Elliott, Brian, Keren Osman, Eileen Scigliano, et al.. (2011). Combining FDG-PET/CT with laboratory data yields superior results for prediction of relapse in multiple myeloma*. European Journal Of Haematology. 86(4). 289–298. 28 indexed citations
18.
Osman, Keren, Brian Elliott, John Mandeli, et al.. (2010). Non‐myeloablative conditioning and allogeneic transplantation for multiple myeloma. American Journal of Hematology. 85(4). 249–254. 8 indexed citations
19.
Eisenberger, Andrew, Brian Elliott, & Howard L. Kaufman. (2006). Viral Vaccines for Cancer Immunotherapy. Hematology/Oncology Clinics of North America. 20(3). 661–687. 10 indexed citations
20.
Seibert, F. J., et al.. (2003). External fixation in trauma of the foot and ankle. Clinics in Podiatric Medicine and Surgery. 20(1). 159–180. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vincent Camus Breakdown of academic impact, for papers by Uri Abadi Breakdown of academic impact, for papers by Jean Michel Picquenot Breakdown of academic impact, for papers by Jens Samol Breakdown of academic impact, for papers by Sami Ibrahimi Breakdown of academic impact, for papers by Qingsong Yin Breakdown of academic impact, for papers by Alison N. Gencarelli Breakdown of academic impact, for papers by Mariana Bastos‐Oreiro Breakdown of academic impact, for papers by Muhamad Alhaj Moustafa Breakdown of academic impact, for papers by Ant Uzay
Rankless by CCL
2026